Yes I think we’re going to see some flexibility in the pricing regime across various jurisdictions. A uniform pricing regime may be “fair and equitable”, but if for example you have the major market countries in Europe teetering on whether to reimburse the cost and less wealthy EU countries deciding the cost is too high and rejecting the drug then that is a partial failure of commercialisation as has been experienced with Clinuvel.
Share Price, page-4949
-
- There are more pages in this discussion • 8,105 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$16.33 |
Change
-0.240(1.45%) |
Mkt cap ! $2.087B | |||
| Open | High | Low | Value | Volume |
| $16.49 | $16.62 | $15.60 | $11.97M | 733.8K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 403 | $16.31 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $16.42 | 1763 | 1 |
View Market Depth
| Last trade - 16.10pm 11/11/2024 (20 minute delay) ? |
| NEU (ASX) Chart |